126 related articles for article (PubMed ID: 38482002)
1. Corrigendum: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.
Demeule M; Currie JC; Charfi C; Zgheib A; Cousineau I; Lullier V; Béliveau R; Marsolais C; Annabi B
Front Immunol; 2024; 15():1389603. PubMed ID: 38482002
[TBL] [Abstract][Full Text] [Related]
2. Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.
Demeule M; Currie JC; Charfi C; Zgheib A; Cousineau I; Lullier V; Béliveau R; Marsolais C; Annabi B
Front Immunol; 2024; 15():1355945. PubMed ID: 38482021
[TBL] [Abstract][Full Text] [Related]
3. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
4. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.
Demeule M; Charfi C; Currie JC; Larocque A; Zgheib A; Kozelko S; Béliveau R; Marsolais C; Annabi B
Cancer Sci; 2021 Oct; 112(10):4317-4334. PubMed ID: 34314556
[TBL] [Abstract][Full Text] [Related]
5. The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers.
Currie JC; Demeule M; Charfi C; Zgheib A; Larocque A; Danalache BA; Ouanouki A; Béliveau R; Marsolais C; Annabi B
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454785
[TBL] [Abstract][Full Text] [Related]
6. Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS-STING pathway.
Guo Y; Shen R; Wang F; Wang Y; Xia P; Wu R; Liu X; Ye W; Tian Y; Wang D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6315-6328. PubMed ID: 36745223
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
[No Abstract] [Full Text] [Related]
8. The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells.
Demeule M; Charfi C; Currie JC; Zgheib A; Danalache BA; Béliveau R; Marsolais C; Annabi B
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145658
[No Abstract] [Full Text] [Related]
9. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
[TBL] [Abstract][Full Text] [Related]
10. DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients.
Vasiyani H; Mane M; Rana K; Shinde A; Roy M; Singh J; Gohel D; Currim F; Srivastava R; Singh R
Apoptosis; 2022 Dec; 27(11-12):961-978. PubMed ID: 36018392
[TBL] [Abstract][Full Text] [Related]
11. A recombinant oncolytic influenza virus expressing a PD-L1 antibody induces CD8
Sun F; Xu Y; Deng Z; Yang P
Int Immunopharmacol; 2023 Jul; 120():110323. PubMed ID: 37207446
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum: Crosstalk between cGAS-STING pathway and autophagy in cancer immunity.
Lu Q; Chen Y; Li J; Zhu F; Zheng Z
Front Immunol; 2023; 14():1216456. PubMed ID: 37275881
[TBL] [Abstract][Full Text] [Related]
13. Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma.
Zhu C; Li J; Yao M; Fang C
BMC Oral Health; 2021 Oct; 21(1):506. PubMed ID: 34625078
[TBL] [Abstract][Full Text] [Related]
14. Irradiation combined with PD-L1
Zhao X; Hu S; Zeng L; Liu X; Song Y; Zhang Y; Chen Q; Bai Y; Zhang J; Zhang H; Pan Y; Shao C
iScience; 2022 Aug; 25(8):104690. PubMed ID: 35847556
[TBL] [Abstract][Full Text] [Related]
15. Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy.
Lu Q; Chen R; Du S; Chen C; Pan Y; Luan X; Yang J; Zeng F; He B; Han X; Song Y
Biomaterials; 2022 Dec; 291():121871. PubMed ID: 36323073
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 deficiency sensitizes tumor cells to DNA-PK inhibition and enhances cGAS-STING activation.
Xue Z; Zheng S; Linghu D; Liu B; Yang Y; Chen MK; Huang H; Song J; Li H; Wang J; Hung MC; Zhong D; Sun L
Am J Cancer Res; 2022; 12(5):2363-2375. PubMed ID: 35693073
[TBL] [Abstract][Full Text] [Related]
17. Corrigendum: The cGAS-STING pathway affects vertebral bone but does not promote intervertebral disc cell senescence or degeneration.
Ottone OK; Kim CJ; Collins JA; Risbud MV
Front Immunol; 2023; 14():1201655. PubMed ID: 37180136
[TBL] [Abstract][Full Text] [Related]
18. Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING/IFN-β pathway.
Yuan M; Guo XL; Chen JH; He Y; Liu ZQ; Zhang HP; Ren J; Xu Q
Neoplasma; 2022 Jul; 69(4):807-819. PubMed ID: 35471977
[TBL] [Abstract][Full Text] [Related]
19. STING in tumors: a focus on non-innate immune pathways.
Yang J; Yang M; Wang Y; Sun J; Liu Y; Zhang L; Guo B
Front Cell Dev Biol; 2023; 11():1278461. PubMed ID: 37965570
[TBL] [Abstract][Full Text] [Related]
20. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer.
Meng J; Peng J; Feng J; Maurer J; Li X; Li Y; Yao S; Chu R; Pan X; Li J; Zhang T; Liu L; Zhang Q; Yuan Z; Bu H; Song K; Kong B
J Transl Med; 2021 Oct; 19(1):415. PubMed ID: 34620163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
